CD4 count is non-inferior to viral load for treatment switching in adults with HIV

August 6, 2013

For adults infected with HIV in Thailand a monitoring strategy based on CD4 count (a type of white blood cell) is non-inferior to the recommended monitoring strategy measuring the amount of HIV virus in a patient's blood, to determine when to switch from first-line to more costly second-line antiretroviral treatment according to a clinical trial published this week in PLOS Medicine.

The study was conducted by an international team of researchers led by Marc Lallemant from Chiang Mai University, Thailand and the Harvard School of Public Health, United States and provides reassurance for health centres in resource-limited setting using CD4 counts alone to monitor treatment of patients with HIV.

The clinical trial included 716 with HIV in Thailand who were starting antiretroviral therapy for the first time. The amount of HIV virus in the patients' blood (known as viral load) as well as CD4 count was measured for each patient every 3 months but for patients randomized to one of the clinical trial's arms physicians only had access to CD4 counts to measure response to therapy and determine whether to switch to second-line anti-HIV drugs, whereas the other arm used both viral load and CD4-count to monitor treatment and viral load measurements were used to determine whether to switch or not. The researchers followed-up the patients for three years after they initiated treatment and compared the number of patients with clinical failure (a very low CD4 count, the onset of AIDS, or death) between the two arms. Overall, 58 patients (30 in the viral load arm and 28 in the CD4 count arm) reached the primary endpoint of clinical failure, which meant that the cumulative risk of clinical failure at 3 years was not statistically different between arms using the different monitoring strategies.

The researchers also found that the probability of a treatment switch was similar in the two arms, but the average time from treatment initiation to treatment switch and the average duration of a high viral load after treatment switch were both longer in the CD4 arm than in the viral load arm. Finally, the future-drug option score, a measure of viral drug resistance profiles, was similar in the two arms at the time of treatment switch.

The authors say, "These findings confirm that access to life-saving [antiretroviral] treatment should continue to be expanded even in settings without virological monitoring, and provide reassurance to treatment programs currently based on CD4 monitoring alone, as [] measurement becomes more affordable and feasible in resource limited settings."

Explore further: Only one-third of HIV-positive patients remain in care before starting treatment

More information: Jourdain G, Le Coeur S, Ngo-Giang-Huong N, Traisathit P, Cressey TR, et al. (2013) Switching HIV Treatment in Adults Based on CD4 Count Versus Viral Load Monitoring: A Randomized, Non-Inferiority Trial in Thailand. PLoS Med 10(8): e1001494. doi:10.1371/journal.pmed.1001494

Related Stories

HIV treatment use increases in the US

September 3, 2012

Between 2000 and 2008, the proportion of HIV-infected patients in the U.S. receiving effective treatment known as highly active antiretroviral therapy (HAART) increased, and HIV-infected patients appeared to be less infectious ...

Early therapy for HIV vital

February 1, 2013

New insight into the optimal timing of therapy for HIV infection could give patients a better chance of responding to potential cure strategies of the future.

Recommended for you

Videos reveal how HIV spreads in real time

October 2, 2015

How retroviruses like HIV spread in their hosts had been unknown—until a Yale team devised a way to watch it actually happen in a living organism. The elaborate and sometimes surprising steps the virus takes to reach and ...

Researchers find proteins that shut down HIV-1

September 30, 2015

A pair of studies by researchers at the University of Massachusetts Medical School, the University of Trento in Italy, and the University of Geneva in Switzerland, point to a promising new anti-retroviral strategy for combating ...

An antibody that can attack HIV in new ways

September 11, 2015

Proteins called broadly neutralizing antibodies (bNAbs) are a promising key to the prevention of infection by HIV, the virus that causes AIDS. bNAbs have been found in blood samples from some HIV patients whose immune systems ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.